Atypical Subtrochanteric Femoral Fracture in a Patient with Non-metatatic Breast Cancer on Zoledronic Acid Therapy: A Case Report.
- Author:
Dae Hee LEE
1
;
Sang Wook LEE
Author Information
1. Department of Orthopeadic Surgery, Konyang University, College of Medicine, Daejeon, Korea. todayzic@lycos.co.kr
- Publication Type:Case Report
- Keywords:
Atypical fracture;
Breast cancer;
Zoledronic acid
- MeSH:
Breast;
Breast Neoplasms;
Diphosphonates;
Female;
Femoral Fractures;
Humans;
Imidazoles
- From:Journal of Korean Orthopaedic Research Society
2012;15(2):72-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The bisphosphonate is known for its ability to reduce bone loss in osteoporotic and osseous metastatic conditions. The side effects have been reported after long-term bisphosphonate therapy. We report the case of a woman who sustained atypical subtrochanteric femoral fracture while being on zoledronic acid (Zometa(R), Novartis) therapy for more than 4 years.